↓ Skip to main content

A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Overview of attention for article published in Clinical Cancer Research, March 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
93 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Published in
Clinical Cancer Research, March 2011
DOI 10.1158/1078-0432.ccr-10-2525
Pubmed ID
Authors

Ji-Youn Han, Soo-Hyun Lee, Nam Jin Yoo, Lee Suk Hyung, Yoon Joo Moon, Tak Yun, Heung Tae Kim, Jin Soo Lee

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 54 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 18%
Researcher 8 15%
Student > Bachelor 6 11%
Other 6 11%
Student > Ph. D. Student 6 11%
Other 9 16%
Unknown 10 18%
Readers by discipline Count As %
Medicine and Dentistry 25 45%
Nursing and Health Professions 5 9%
Biochemistry, Genetics and Molecular Biology 4 7%
Agricultural and Biological Sciences 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Other 1 2%
Unknown 14 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2022.
All research outputs
#4,078,668
of 21,448,133 outputs
Outputs from Clinical Cancer Research
#3,531
of 12,206 outputs
Outputs of similar age
#67,529
of 288,587 outputs
Outputs of similar age from Clinical Cancer Research
#105
of 266 outputs
Altmetric has tracked 21,448,133 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,206 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 266 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.